Best Practice & Research Clinical Endocrinology & Metabolism
Volume 20, Issue 2 , Pages 311-330 , June 2006

Treatment of PCOS in adolescence

  • Julia Warren-Ulanch, MD (Adult and Pediatric Endocrinology Fellow, University of Pittsburgh Medical Center)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +1 412 692 7466; fax: +1 412 692 5834.
  • Silva Arslanian, MD (Professor of Pediatrics, University of Pittsburgh School of Medicine; Director, Weight Management and Wellness Center; and Director, General Clinical Research Center)

References 

  1. Trent ME, Rich M, Austin SB, et al. Fertility concerns and sexual behavior in adolescent girls with polycystic ovary syndrome: implications for quality of life. Journal of Pediatric and Adolescent Gynecology. 2003;16:33–37
  2. Trent M, Austin SB, Rich M, et al. Overweight status of adolescent girls with polycystic ovary syndrome: body mass index as mediator of quality of life. Ambulatory Pediatrics. 2005;5:107–111
  3. Zawadzki J, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In:  Dunaif A,  Givens J,  Haseltine F,  Haseltine G editor. Polycystic Ovary Syndrome. 1st edn. Oxford, England: Blackwell Scientific; 1992;p. 377–384
  4. Rosenfield RL, Ghai K, Ehrmann DA, et al. Diagnosis of the polycystic ovary syndrome in adolescence: comparison of adolescent and adult hyperandrogenism. Journal of Pediatric Endocrinology and Metabolism. 2000;13(supplement 5):1285–1289
  5. Creatsas G, Koliopoulos C, Mastorakos G. Combined oral contraceptive treatment of adolescent girls with polycystic ovary syndrome. Lipid profile. Annals of the New York Academy of Sciences. 2000;900:245–252
  6. Apter D, Vihko R. Premenarcheal endocrine changes in relation to age at menarche. Clinical Endocrinology (Oxford). 1985;22:753–760
  7. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and Sterility, 2004; 81, pp. 19–25.
  8. Bridges NA, Cooke A, Healy MJ, et al. Standards for ovarian volume in childhood and puberty. Fertility and Sterility. 1993;60:456–460
  9. Baumann E, Rosenfield R. Polycystic ovary syndrome in adolescence. Endocrinologist. 2002;12:333–348
  10. van Hooff MH, Voorhorst FJ, Kaptein MB, et al. Predictive value of menstrual cycle pattern, body mass index, hormone levels and polycystic ovaries at age 15 years for oligo-amenorrhoea at age 18 years. Human Reproduction. 2004;19:383–392
  11. Homburg R, Lambalk CB. Polycystic ovary syndrome in adolescence—a therapeutic conundrum. Human Reproduction. 2004;19:1039–1042
  12. Ibanez L, Valls C, Ferrer A, et al. Sensitization to insulin induces ovulation in nonobese adolescents with anovulatory hyperandrogenism. The Journal of Clinical Endocrinology and Metabolism. 2001;86:3595–3598
  13. Plouffe L. Disorders of excessive hair growth in the adolescent. Obstetrics and Gynecology Clinics of North America. 2000;27:79–99
  14. Dramusic V, Goh VH, Rajan U, et al. Clinical, endocrinologic, and ultrasonographic features of polycystic ovary syndrome in Singaporean adolescents. Journal of Pediatric and Adolescent Gynecology. 1997;10:125–132
  15. Ibanez L, de Zegher F. Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity. The Journal of Clinical Endocrinology and Metabolism. 2004;89:1592–1597
  16. Wild RA. Obesity, lipids, cardiovascular risk, and androgen excess. The American Journal of Medicine. 1995;98:27S–32S
  17. Silfen ME, Denburg MR, Manibo AM, et al. Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between nonobese and obese adolescents. The Journal of Clinical Endocrinology and Metabolism. 2003;88:4682–4688
  18. Ibanez L, Ferrer A, Ong K, et al. Insulin sensitization early after menarche prevents progression from precocious pubarche to polycystic ovary syndrome. Journal of Pediatrics. 2004;144:23–29
  19. Salmi DJ, Zisser HC, Jovanovic L. Screening for and treatment of polycystic ovary syndrome in teenagers. Experimental Biology and Medicine (Maywood). 2004;229:369–377
  20. Cedars MI. Polycystic ovary syndrome: what is it and how should we treat it?. Journal of Pediatrics. 2004;144:4–6
  21. Holte J. Polycystic ovary syndrome and insulin resistance: thrifty genes struggling with over-feeding and sedentary life style?. Journal of Endocrinological Investigation. 1998;21:589–601
  22. Ibanez L, Potau N, Francois I, et al. Precocious pubarche, hyperinsulinism, and ovarian hyperandrogenism in girls: relation to reduced fetal growth. The Journal of Clinical Endocrinology and Metabolism. 1998;83:3558–3562
  23. Ibanez L, Potau N, Ferrer A, et al. Reduced ovulation rate in adolescent girls born small for gestational age. The Journal of Clinical Endocrinology and Metabolism. 2002;87:3391–3393
  24. Barker DJ, Hales CN, Fall CH, et al. Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth. Diabetologia. 1993;36:62–67
  25. Hales CN, Barker DJ, Clark PM, et al. Fetal and infant growth and impaired glucose tolerance at age 64. BMJ. 1991;303:1019–1022
  26. Harding JE. The nutritional basis of the fetal origins of adult disease. International Journal of Epidemiology. 2001;30:15–23
  27. Phipps K, Barker DJ, Hales CN, et al. Fetal growth and impaired glucose tolerance in men and women. Diabetologia. 1993;36:225–228
  28. Garnett SP, Cowell CT, Baur LA, et al. Abdominal fat and birth size in healthy prepubertal children. International Journal of Obesity and Related Metabolic Disorders. 2001;25:1667–1673
  29. Neville KA, Walker JL. Precocious pubarche is associated with SGA, prematurity, weight gain, and obesity. Archives of Disease in Childhood. 2005;90:258–261
  30. Laitinen J, Taponen S, Martikainen H, et al. Body size from birth to adulthood as a predictor of self-reported polycystic ovary syndrome symptoms. International Journal of Obesity and Related Metabolic Disorders. 2003;27:710–715
  31. Jaquet D, Leger J, Chevenne D, et al. Intrauterine growth retardation predisposes to insulin resistance but not to hyperandrogenism in young women. The Journal of Clinical Endocrinology and Metabolism. 1999;84:3945–3949
  32. Ibanez L, Potau N, Virdis R, et al. Postpubertal outcome in girls diagnosed of premature pubarche during childhood: increased frequency of functional ovarian hyperandrogenism. The Journal of Clinical Endocrinology and Metabolism. 1993;76:1599–1603
  33. Ibanez L, Valls C, Marcos MV, et al. Insulin sensitization for girls with precocious pubarche and with risk for polycystic ovary syndrome: effects of prepubertal initiation and postpubertal discontinuation of metformin treatment. The Journal of Clinical Endocrinology and Metabolism. 2004;89:4331–4337
  34. Kaplowitz PB, Slora EJ, Wasserman RC, et al. Earlier onset of puberty in girls: relation to increased body mass index and race. Pediatrics. 2001;108:347–353
  35. Pasquali R, Casimirri F, Antenucci D, et al. Relationship between onset of obesity and onset of oligomenorrhea or amenorrhea in females with obesity and polycystic ovaries. In:  Flamigni C,  Venturoli S,  Givens J editor. Adolescence in Females. Chicago, IL: Year Book; 1985;p. 363–365
  36. Remer T, Manz F. Role of nutritional status in the regulation of adrenarche. The Journal of Clinical Endocrinology and Metabolism. 1999;84:3936–3944
  37. Taponen S, Martikainen H, Jarvelin MR, et al. Hormonal profile of women with self-reported symptoms of oligomenorrhea and/or hirsutism: Northern Finland birth cohort 1966 study. The Journal of Clinical Endocrinology and Metabolism. 2003;88:141–147
  38. Jabbar M, Pugliese M, Fort P, et al. Excess weight and precocious pubarche in children: alterations of the adrenocortical hormones. Journal of the American College of Nutrition. 1991;10:289–296
  39. Apter D, Butzow T, Laughlin GA, et al. Metabolic features of polycystic ovary syndrome are found in adolescent girls with hyperandrogenism. The Journal of Clinical Endocrinology and Metabolism. 1995;80:2966–2973
  40. Lewy VD, Danadian K, Witchel SF, et al. Early metabolic abnormalities in adolescent girls with polycystic ovarian syndrome. Journal of Pediatrics. 2001;138:38–44
  41. Legro RS, Finegood D, Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. The Journal of Clinical Endocrinology and Metabolism. 1998;83:2694–2698
  42. Arslanian S. Insulin resistance and insulin secretion in childhood and adolescence: their role in type 2 diabetes in youth. In:  Silink M,  Kida K,  Rosenbloom A editor. Type 2 Diabetes in Childhood and Adolescence. London: Martin Dunitz Publishing Company; 2003;p. 93–116
  43. Kent SC, Legro RS. Polycystic ovary syndrome in adolescents. Adolescent Medicine. 2002;13:73–88[vi]
  44. Palmert MR, Gordon CM, Kartashov AI, et al. Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome. The Journal of Clinical Endocrinology and Metabolism. 2002;87:1017–1023
  45. Mastorakos G, Koliopoulos C, Creatsas G. Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives. Fertility and Sterility. 2002;77:919–927
  46. Robbins DC, Andersen L, Bowsher R, et al. Report of the American Diabetes Association's Task Force on standardization of the insulin assay. Diabetes. 1996;45:242–256
  47. Dunaif A, Finegood DT. Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. The Journal of Clinical Endocrinology and Metabolism. 1996;81:942–947
  48. Ehrmann DA, Sturis J, Byrne MM, et al. Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. The Journal of Clinical Investigation. 1995;96:520–527
  49. Arslanian SA, Lewy VD, Danadian K. Glucose intolerance in obese adolescents with polycystic ovary syndrome: roles of insulin resistance and beta-cell dysfunction and risk of cardiovascular disease. The Journal of Clinical Endocrinology and Metabolism. 2001;86:66–71
  50. Legro RS. Detection of insulin resistance and its treatment in adolescents with polycystic ovary syndrome. Journal of Pediatric Endocrinology & Metabolism. 2002;15(supplement 5):1367–1378
  51. Legro RS, Kunselman AR, Dodson WC, et al. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. The Journal of Clinical Endocrinology and Metabolism. 1999;84:165–169
  52. Saad R, Gungor N, Arslanian S. Progression from normal glucose tolerance to type 2 diabetes in a young girl: longitudinal changes in insulin sensitivity and secretion assessed by the clamp technique and surrogate estimates. Pediatric Diabetes. 2005;6:95–99
  53. Ibanez L, De Zegher F. Flutamide–metformin therapy to reduce fat mass in hyperinsulinemic ovarian hyperandrogenism: effects in adolescents and in women on third-generation oral contraception. The Journal of Clinical Endocrinology and Metabolism. 2003;88:4720–4724
  54. Ibanez L, Ong K, Ferrer A, et al. Low-dose flutamide–metformin therapy reverses insulin resistance and reduces fat mass in nonobese adolescents with ovarian hyperandrogenism. The Journal of Clinical Endocrinology and Metabolism. 2003;88:2600–2606
  55. Bacha F, Saad R, Gungor N, et al. Adiponectin in youth: relationship to visceral adiposity, insulin sensitivity, and beta-cell function. Diabetes Care. 2004;27:547–552
  56. Morin-Papunen L, Rautio K, Ruokonen A, et al. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. The Journal of Clinical Endocrinology and Metabolism. 2003;88:4649–4654
  57. Sayin NC, Gucer F, Balkanli-Kaplan P, et al. Elevated serum TNF-alpha levels in normal-weight women with polycystic ovaries or the polycystic ovary syndrome. The Journal of Reproductive Medicine. 2003;48:165–170
  58. Tarkun I, Canturk Z, Arslan BC, et al. The plasminogen activator system in young and lean women with polycystic ovary syndrome. Endocrine Journal. 2004;51:467–472
  59. Pierpoint T, McKeigue PM, Isaacs AJ, et al. Mortality of women with polycystic ovary syndrome at long-term follow-up. Journal of Clinical Epidemiology. 1998;51:581–586
  60. Wild S, Pierpoint T, McKeigue P, et al. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clinical Endocrinology (Oxford). 2000;52:595–600
  61. Diamanti-Kandarakis E, Spina G, Kouli C, et al. Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. The Journal of Clinical Endocrinology and Metabolism. 2001;86:4666–4673
  62. Lakhani K, Hardiman P, Seifalian AM. Intima-media thickness of elastic and muscular arteries of young women with polycystic ovaries. Atherosclerosis. 2004;175:353–359
  63. Meyer C, McGrath BP, Cameron J, et al. Vascular dysfunction and metabolic parameters in polycystic ovary syndrome. The Journal of Clinical Endocrinology and Metabolism. 2005;90:4630–4635
  64. Orio F, Palomba S, Cascella T, et al. Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. The Journal of Clinical Endocrinology and Metabolism. 2004;89:4588–4593
  65. Vryonidou A, Papatheodorou A, Tavridou A, et al. Association of hyperandrogenemic and metabolic phenotype with carotid intima-media thickness in young women with polycystic ovary syndrome. The Journal of Clinical Endocrinology and Metabolism. 2005;90:2740–2746
  66. Rosenfield RL. Ovarian and adrenal function in polycystic ovary syndrome. Endocrinology and Metabolism Clinics of North America. 1999;28:265–293
  67. Moghetti P, Castello R, Negri C, et al. Insulin infusion amplifies 17 alpha-hydroxycorticosteroid intermediates response to adrenocorticotropin in hyperandrogenic women: apparent relative impairment of 17,20-lyase activity. The Journal of Clinical Endocrinology and Metabolism. 1996;81:881–886
  68. Arslanian SA, Lewy V, Danadian K, et al. Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. The Journal of Clinical Endocrinology and Metabolism. 2002;87:1555–1559
  69. Azziz R, Kashar-Miller MD. Family history as a risk factor for the polycystic ovary syndrome. Journal of Pediatric Endocrinology & Metabolism. 2000;13(supplement 5):1303–1306
  70. Colilla S, Cox NJ, Ehrmann DA. Heritability of insulin secretion and insulin action in women with polycystic ovary syndrome and their first degree relatives. The Journal of Clinical Endocrinology and Metabolism. 2001;86:2027–2031
  71. Yildiz BO, Yarali H, Oguz H, et al. Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome. The Journal of Clinical Endocrinology and Metabolism. 2003;88:2031–2036
  72. Azziz R. The time has come to simplify the evaluation of the hirsute patient. Fertility and Sterility. 2000;74:870–872
  73. Pfeifer SM, Dayal M. Treatment of the adolescent patient with polycystic ovary syndrome. Obstetrics and Gynecology Clinics of North America. 2003;30:337–352
  74. Carbunaru G, Prasad P, Scoccia B, et al. The hormonal phenotype of Nonclassic 3 beta-hydroxysteroid dehydrogenase (HSD3B) deficiency in hyperandrogenic females is associated with insulin-resistant polycystic ovary syndrome and is not a variant of inherited HSD3B2 deficiency. The Journal of Clinical Endocrinology and Metabolism. 2004;89:783–794
  75. New MI. An update of congenital adrenal hyperplasia. Annals of the New York Academy of Sciences. 2004;1038:14–43
  76. Uusitupa M, Louheranta A, Lindstrom J, et al. The finnish diabetes prevention study. The British Journal of Nutrition. 2000;83(supplement 1):S137–S142
  77. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. The New England Journal of Medicine. 2002;346:393–403
  78. Kiddy DS, Hamilton-Fairley D, Bush A, et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clinical Endocrinology (Oxford). 1992;36:105–111
  79. Guzick DS, Wing R, Smith D, et al. Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women. Fertility and Sterility. 1994;61:598–604
  80. Pasquali R, Antenucci D, Casimirri F, et al. Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. The Journal of Clinical Endocrinology and Metabolism. 1989;68:173–179
  81. Randeva HS, Lewandowski KC, Drzewoski J, et al. Exercise decreases plasma total homocysteine in overweight young women with polycystic ovary syndrome. The Journal of Clinical Endocrinology and Metabolism. 2002;87:4496–4501
  82. Rosenbaum M, Leibel RL, Hirsch J. Obesity. The New England Journal of Medicine. 1997;337:396–407
  83. Epstein LH, Valoski A, Wing RR, et al. Ten-year follow-up of behavioral, family-based treatment for obese children. JMMA. 1990;264:2519–2523
  84. Kirk S, Zeller M, Claytor R, et al. The relationship of health outcomes to improvement in BMI in children and adolescents. Obesity Research. 2005;13:876–882
  85. Hoeger KM, Kochman L, Wixom N, et al. A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertility and Sterility. 2004;82:421–429
  86. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception. 2000;62:29–38
  87. Ibanez L, De Zegher F. Flutamide–metformin plus an oral contraceptive (OC) for young women with polycystic ovary syndrome: switch from third- to fourth-generation OC reduces body adiposity. Human Reproduction. 2004;19:1725–1727
  88. Arslanian S, Witchel SF. Polycystic ovary syndrome in adolescents: is there an epidemic?. Current Opinion in Endocrinology Diabetes. 2002;9:32–42
  89. Ibanez L, Potau N, Marcos MV, et al. Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism in nonobese, adolescent girls: effect of flutamide. The Journal of Clinical Endocrinology and Metabolism. 2000;85:3251–3255
  90. Glueck CJ, Wang P, Fontaine R, et al. Metformin to restore normal menses in oligo-amenorrheic teenage girls with polycystic ovary syndrome (PCOS). The Journal of Adolescent Health. 2001;29:160–169
  91. Ibanez L, Potau N, Ferrer A, et al. Anovulation in eumenorrheic, nonobese adolescent girls born small for gestational age: insulin sensitization induces ovulation, increases lean body mass, and reduces abdominal fat excess, dyslipidemia, and subclinical hyperandrogenism. The Journal of Clinical Endocrinology and Metabolism. 2002;87:5702–5705
  92. Arlt W, Auchus RJ, Miller WL. Thiazolidinediones but not metformin directly inhibit the steroidogenic enzymes P450c17 and 3beta -hydroxysteroid dehydrogenase. The Journal of Biological Chemistry. 2001;276:16767–16771
  93. Guido M, Romualdi D, Suriano R, et al. Effect of pioglitazone treatment on the adrenal androgen response to corticotrophin in obese patients with polycystic ovary syndrome. Human Reproduction. 2004;19:534–539
  94. Sepilian V, Nagamani M. Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance. The Journal of Clinical Endocrinology and Metabolism. 2005;90:60–65
  95. Ortega-Gonzalez C, Luna S, Hernandez L, et al. Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. The Journal of Clinical Endocrinology and Metabolism. 2005;90:1360–1365
  96. Guttmann-Bauman I. Approach to adolescent polycystic ovary syndrome (PCOS) in the pediatric endocrine community in the USA. Journal of Pediatric Endocrinology and Metabolism. 2005;18:499–506
  97. Simard J, Luthy I, Guay J, et al. Characteristics of interaction of the antiandrogen flutamide with the androgen receptor in various target tissues. Molecular and Cellular Endocrinology. 1986;44:261–270
  98. Sahin Y, Dilber S, Kelestimur F. Comparison of Diane 35 and Diane 35 plus finasteride in the treatment of hirsutism. Fertility and Sterility. 2001;75:496–500
  99. Golland IM, Elstein ME. Results of an open one-year study with Diane-35 in women with polycystic ovarian syndrome. Annals of the New York Academy of Sciences. 1993;687:263–271
  100. van Wayjen RG, van den Ende A. Experience in the long-term treatment of patients with hirsutism and/or acne with cyproterone acetate-containing preparations: efficacy, metabolic and endocrine effects. Experimental and Clinical Endocrinology and Diabetes. 1995;103:241–251
  101. Harborne L, Fleming R, Lyall H, et al. Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. The Journal of Clinical Endocrinology and Metabolism. 2003;88:4116–4123
  102. Seaman HE, de Vries CS, Farmer RD. Venous thromboembolism associated with cyproterone acetate in combination with ethinyloestradiol (Dianette): observational studies using the UK General Practice Research Database. Pharmacoepidemiology and Drug Safety. 2004;13:427–436
  103. Ganie MA, Khurana ML, Eunice M, et al. Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study. The Journal of Clinical Endocrinology and Metabolism. 2004;89:2756–2762
  104. Zulian E, Sartorato P, Benedini S, et al. Spironolactone in the treatment of polycystic ovary syndrome: effects on clinical features, insulin sensitivity and lipid profile. Journal of Endocrinological Investigation. 2005;28:49–53
  105. Ibanez L, de Zegher F. Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of metformin at the start and after more than one year of therapy. The Journal of Clinical Endocrinology and Metabolism. 2005;90:39–43
  106. Harborne LR, Sattar N, Norman JE, et al. Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. The Journal of Clinical Endocrinology and Metabolism. 2005;90:4593–4598
  107. Ruchhoft EA, Elkind-Hirsch KE, Malinak R. Pituitary function is altered during the same cycle in women with polycystic ovary syndrome treated with continuous or cyclic oral contraceptives or a gonadotropin-releasing hormone agonist. Fertility and Sterility. 1996;66:54–60
  108. Wiegratz I, Kuhl H. Long-cycle treatment with oral contraceptives. Drugs. 2004;64:2447–2462
  109. Diamanti-Kandarakis E, Baillargeon JP, Iuorno MJ, et al. A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills. The Journal of Clinical Endocrinology and Metabolism. 2003;88:1927–1932
  110. Vignini M, Pelfini C, Montanari L. A cyproterone acetate-ethinyl estradiol combination in the treatment of acne. Data of a survey of gynecologists. Minerva Ginecologica. 1988;40:125–132
  111. Yuksel O, Dokmetas HS, Topcu S, et al. Relationship between bone mineral density and insulin resistance in polycystic ovary syndrome. Journal of Bone and Mineral Metabolism. 2001;19:257–262
  112. Zborowski JV, Cauley JA, Talbott EO, et al. Clinical Review 116: Bone mineral density, androgens, and the polycystic ovary: the complex and controversial issue of androgenic influence in female bone. The Journal of Clinical Endocrinology and Metabolism. 2000;85:3496–3506
  113. Cromer BA, Stager M, Bonny A, et al. Depot medroxyprogesterone acetate, oral contraceptives and bone mineral density in a cohort of adolescent girls. The Journal of Adolescent Health. 2004;35:434–441
  114. Warren-Ulanch J, Greenspan S, Arslanian S. Bone mass and turnover in adolescents with polycystic ovary syndrome: effects of treatment with metformin. 87th Annual Meeting of the Endocrine Society 2005, [Program and Abstracts: #P2-395, p. 453].

PII: S1521-690X(06)00016-9

doi: 10.1016/j.beem.2006.02.002

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 20, Issue 2 , Pages 311-330 , June 2006

Article Tools

* Image Usage & Resolution